newsfilter
← Latest News
GlobeNewswire·

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,